AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.45 |
Market Cap | 166.56M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.37 |
PE Ratio (ttm) | -3.09 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.48 |
Volume | 455,532 |
Avg. Volume (20D) | 443,734 |
Open | 1.25 |
Previous Close | 1.24 |
Day's Range | 1.13 - 1.26 |
52-Week Range | 1.11 - 2.21 |
Beta | undefined |
About BDSX
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. ...
Analyst Forecast
According to 4 analyst ratings, the average rating for BDSX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 162.01% from the latest price.
Next Earnings Release
Analysts project revenue of $19.83M, reflecting a 35.19% YoY growth and earnings per share of -0.06, making a -40.00% decrease YoY.
2 months ago · businesswire.com
Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the t...